Ann: Epichem achieves ISO 9001 2015 certification-PAA.AX, page-4

We must look at the direction as investors. Australians aren't much good at tech investment since we seem too fond of safe, current dividends, which is a mistake in this sector and part of what holds our tech sector back. Epichem is growing strongly and profitable in its own right. It has customers in over 30 countries, its reputation is growing and international, helped by winning the DNDi contract again which is a public vote of confidence in Epichem's quality services and it's now gotten a difficult to get international accreditation. Furthermore, there are strong expertise synergies with the other PAA division Pitney Pharmaceuticals. The important point is Epichem is headed in the right direction.

Meanwhile, Pitney has given up its promising Mucin project to narrow its focus onto the highly promising PPL-1, (the Mucin project will still pay a royalty for the work done - eventually) the Cambridge dog tests are now 2.5 months old, Dr Firmberger has requested the recommencement of her trials at the Animal Referral Hospital- which is another big vote of confidence from a group that has experience with the drug and another Australian veterinary group has asked to join in. We now are headed to phase II of the human trials I am a bit frustrated at the time it's taking, but it can't be long now the reformulated pills are ready.

The quality of PAA staff is world class and they have large share holdings and have been buying more.

Good reasons to look ahead positively.